Dermata Therapeutics, Inc. (NasdaqCM: DRMA)
Health Care · Biotechnology · US
$1.61
+13.03% today · -75.6% 1Y
Dermata Therapeutics, Inc. (NasdaqCM: DRMA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.71M and employs 9 people.
Over the last twelve months the share price has lost 75.6%, trading between 0.95 and 6.22.
Tweenvest scores Dermata Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
DRMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.71M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.33
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- $6.22
- 52-week low
- $0.95
- Avg volume (3M)
- —
- Shares outstanding
- 4.02M
- Employees
- 9
- Next earnings
- —
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
- ISIN
- US2498455045
- Founded
- 2014
- Listed since
- Aug 13, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.36 | -1.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.60 | -0.37% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | 0.00% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.58 | -0.59% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.75 | -6.98% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.